Literature DB >> 1676798

Simultaneous treatment of cytomegalovirus retinitis with ganciclovir and foscarnet.

M R Nelson, G Barter, D Hawkins, B G Gazzard.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1676798     DOI： 10.1016/0140-6736(91)90385-3

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  7 in total

Review 1.  The management of cytomegalovirus retinitis in AIDS.

Authors:  B Dhillon
Journal:  Br J Ophthalmol       Date:  1994-01       Impact factor: 4.638

2.  The role of ganciclovir for the management of cytomegalovirus retinitis in HIV patients: Pharmacological review and update on new developments.

Authors:  A Tseng; M Foisy
Journal:  Can J Infect Dis       Date:  1996-05

3.  Foscarnet and ganciclovir combination therapy for CMV disease in HIV-infected patients.

Authors:  B Salzberger; A Stoehr; W Heise; G Fätkenheuer; A Schwenk; C Franzen; O Cornely; M Schrappe
Journal:  Infection       Date:  1994 May-Jun       Impact factor: 3.553

Review 4.  Ocular complications of the acquired immunodeficiency syndrome. Focus on the treatment of cytomegalovirus retinitis with ganciclovir and foscarnet.

Authors:  W J Keijer; D M Burger; G H Neuteboom; J L Vrooland; P L Meenhorst; C H Koks; J H Beijnen
Journal:  Pharm World Sci       Date:  1993-04-23

Review 5.  Combined and alternating ganciclovir and foscarnet in acute and maintenance therapy of human immunodeficiency virus-related cytomegalovirus encephalitis refractory to ganciclovir alone. A case report and review of the literature.

Authors:  M Peters; U Timm; D Schürmann; H D Pohle; B Ruf
Journal:  Clin Investig       Date:  1992-05

Review 6.  Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections.

Authors:  A J Wagstaff; H M Bryson
Journal:  Drugs       Date:  1994-08       Impact factor: 9.546

Review 7.  Ganciclovir. An update of its therapeutic use in cytomegalovirus infection.

Authors:  A Markham; D Faulds
Journal:  Drugs       Date:  1994-09       Impact factor: 9.546
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.